Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.64 |
| ▸ | FAP | Q12884 | 2/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.64 |
| ▸ | ACE | P12821 | 6/20 | 0.58 |
| ▸ | REN | P00797 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PEPD | P12955 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729262 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30729240 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL22498704 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30179346 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL7405423 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL231857 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5278976 | 1.00 | DPP4 (0.64) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL25276458 | 0.95 | DPP4 (0.59) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1646849 | 0.95 | DPP4 (0.59) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1646847 | 0.95 | DPP4 (0.59) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116804677-A | Biomarker for early detection of aspiration pneumonia and application thereof | 福建医科大学附属第二医院 | 2023-09-26 | — | — | CN | claimed |
| EP-4678652-A1 | METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20250172567-A1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12135329-B2 | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-05 | — | — | US | disclosed |
| WO-2024219480-A1 | METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2024-10-24 | — | — | WO | disclosed |
| US-20240315296-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-26 | — | — | US | disclosed |
| EP-4364582-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | CJ Cheiljedang Corporation (KR) | 2024-05-08 | — | — | EP | disclosed |
| US-20230408528-A1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) ANDCLEAVED HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-21 | — | — | US | disclosed |
| US-11826758-B2 | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-28 | — | — | US | disclosed |
| CN-116804677-A | Biomarker for early detection of aspiration pneumonia and application thereof | 福建医科大学附属第二医院 | 2023-09-26 | — | — | CN | disclosed |
| EP-4135660-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2023277549-A1 | PEPTIDE COMPOUNDS FOR FLAVOR MODULATING | 씨제이제일제당 (주) | 2023-01-05 | — | — | WO | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| EP-2279417-B1 | METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF | GEORGIA TECH RES INST (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20120004854-A1 | METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION | 2012-01-05 | — | — | US | disclosed |
| EP-2279417-A1 | METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF | Georgia Tech Research Corporation (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009151967-A1 | METABOLIC BIOMARKERS FOR OVARIAN CANCER AND METHODS OF USE THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20040024180-A1 | Process for the production of 2,5 -diketopiperazines,2,5-diketopiperazines , dipeptides and their use thereof | DEGUSSA AG (DE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024180-A1 | Process for the production of 2,5 -diketopiperazines,2,5-diketopiperazines , dipeptides and their use thereof | DHPS, DPP7, VIP | DPP4 14/4885FAP 175/4885DPP8 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.